1	Brief Communication			
2 3 4	Immune history shapes human antibody responses to H5N1 influenza viruses			
5 6 7 8 9	Tyler A. Garretson <sup>1,#</sup> , Jiaojiao Liu <sup>1,#</sup> , Shuk Hang Li <sup>1,#</sup> , Gabrielle Scher <sup>1,#</sup> , Jefferson J.S. Santos <sup>1,#</sup> , Glenn Hogan <sup>2</sup> , Marcos Costa Vieira <sup>3</sup> , Colleen Furey <sup>1</sup> , Reilly K. Atkinson <sup>1</sup> , Naiqing Ye <sup>1</sup> , Jordan Ort <sup>1</sup> , Kangchon Kim <sup>3</sup> , Kevin A. Hernandez <sup>1</sup> , Theresa Eilola <sup>1</sup> , David			
10 11 12 13 14 15 16	C. Schultz <sup>4</sup> , Sara Cherry <sup>2</sup> , Sarah Cobey <sup>3</sup> , Scott E. Hensley <sup>1,*</sup> <sup>1</sup> Department of Microbiology, Perelman School of Medicine, University of Pennsylvani Philadelphia, Pennsylvania <sup>2</sup> Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania			
17 18 19 20 21	<sup>3</sup> Department of Ecology & Evolution, The University of Chicago, Chicago, IL <sup>4</sup> Department of Biochemistry & Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania			
22 23				
24 25 26				
27	<sup>#</sup> these authors contributed equally			
28 29	*corresponding author: 402 Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104. Phone: (215) 573-3756. Email: hensley@pennmedicine.upenn.edu			
30 31 32	Running title: Human H5N1 antibody responses			

# 34 Abstract

35	Avian H5N1 influenza viruses are circulating widely in cattle and other mammals and
36	pose a risk for a human pandemic. Previous studies suggest that older humans are
37	more resistant to H5N1 infections due to childhood imprinting with other group 1 viruses
38	(H1N1 and H2N2); however, the immunological basis for this is incompletely understood.
39	Here we show that antibody titers to historical and recent H5N1 strains are highest in
40	older individuals and correlate more strongly with year of birth than with age, consistent
41	with immune imprinting. After vaccination with an A/Vietnam/1203/2004 H5N1 vaccine,
42	both younger and older humans produced H5-reactive antibodies to the vaccine strain
43	and to a clade 2.3.4.4b isolate currently circulating in cattle, with higher seroconversion
44	rates in young children who had lower levels of antibodies before vaccination. These
45	studies suggest that younger individuals might benefit more from vaccination than older
46	individuals in the event of an H5N1 pandemic.
4 77	

### 48 Main text

49	Highly pathogenic avian influenza (HPAI) clade 2.3.4.4b H5 viruses began
50	circulating at high levels in bird populations across the world in 2020 <sup>1-4</sup> and have caused
51	infections in mammals such as foxes, seals, and mink $^{5-8}$ . At the end of 2023, a clade
52	2.3.4.4b H5N1 virus began circulating in dairy cattle in the United States <sup>9</sup> , with
53	widespread transmission between cows <sup>10</sup> . Clade 2.3.4.4b H5N1 viruses do not currently
54	bind well to receptors found in human upper airways <sup>11,12</sup> ; however, widespread
55	circulation in mammals could lead to adaptive substitutions that increase viral
56	attachment, replication, and human transmission <sup>13,14</sup> .
57	Previously circulating H5N1 viruses caused higher mortality rates in younger
58	humans relative to older humans <sup>15,16</sup> . It is possible that immunity elicited by seasonal
59	influenza viruses affects H5N1 susceptibility. Influenza A viruses can be broadly split into
60	2 different phylogenetic groups <sup>17</sup> . Group 1 (H1N1 and H2N2) and group 2 (H3N2)
61	viruses have circulated during distinct times since 1918 (Fig. 1a), and therefore
62	immunity against each of these viruses is partly shaped by an individual's birth year
63	(Extended Fig. 1). Gostic and colleagues proposed that individuals born before 1968
64	may be more refractory to severe disease following H5N1 (a group 1 virus) infection
65	since most of these individuals were likely 'immunologically imprinted' with other group 1
66	viruses (H1N1 and H2N2) in childhood <sup>18</sup> . Although H5N1 is antigenically distinct from
67	H1N1 and H2N2, all three of these viruses share homology in conserved epitopes,
68	including the hemagglutinin (HA) stalk domain <sup>17</sup> . Previous studies reported that H1 stalk-
69	reactive antibodies are more prevalent in older individuals <sup>19,20</sup> ; however, a subsequent
70	study found no clear association with H1 stalk-reactive antibodies and birth year among
71	adults <sup>21</sup> .

We quantified antibodies reactive to group 1 HA stalks (H1 and H5) and group 2
HA stalks (H3 and H7) in serum samples collected in 2017 from 121 healthy adults born

74 between 1927-1998 (19-90 years old at time of sampling). H1 and H5 stalk-reactive 75 antibodies were higher in older adults, although younger adults possessed moderate 76 amounts of these antibodies (Fig. 1b-c). We asked if stalk-reactive antibody levels 77 correlated with the probability of immune imprinting (i.e., initial infection in childhood) with viruses of the same subtype or group, estimated from historical data. H1 and H5 78 79 stalk-reactive antibody titers were both positively correlated with group 1 and H1N1 80 imprinting probabilities (Table S1). We found that group 2 HA stalk antibody levels were 81 generally lower with no obvious correlation between titer and birth year (Fig. 1d-e. Table 82 H3 stalk-reactive antibodies were present in sera at similar levels regardless of 83 donor age (Fig. 1d) and H7 stalk-reactive antibodies were generally low in the sera from 84 most donors (Fia. 1e).

85 Consistent with the group 1 HA stalk titer data, we found that individuals 86 imprinted with group 1 viruses in childhood possessed high levels of antibodies reactive 87 to clade 1 H5 full length HA (A/Vietnam/1203/2004) (Fig. 1f, Table S1) and clade 88 2.3.4.4b H5 full length HAs (A/Pheasant/New York/22-00906-001/2022 and A/Dairy 89 Cattle/Texas/24-008749-002-v/2024) (Fig. 1g, Extended Data Fig. 2, and Table S1). 90 Most of these cross-reactive antibodies were non-neutralizing, although we detected 91 antibodies that neutralized clade 1 and clade 2.3.4.4b H5N1 in rare individuals of all 92 ages (Extended Data Fig. 3). Taken together, our data suggest that childhood 93 exposures to H1N1 and H2N2 prime mostly non-neutralizing group 1 HA stalk antibodies 94 that bind to diverse H5 HAs. 95 Previous studies showed that H5 vaccines elicit HA stalk antibodies in

humans<sup>22,23</sup>; however, it is unknown if H5 vaccines elicit different levels of HA stalk
antibodies in individuals with different birth years. We obtained serum samples collected
from children and adults (born between 1918-2003) before and after administration of a
45 µg dose of an H5N1 (A/Vietnam/1203/2004) unadjuvanted vaccine (ClinicalTrials.gov

#s: NCT00133536, NCT00230750, NCT00115986<sup>24</sup>). Since these clinical studies were 100 101 completed in the years 2005-2006, the participants ranged from 2-97 years of age at 102 time of vaccination. All participants received a prime-boost regiment, and we analyzed serum samples before vaccination and 28 days after the 1<sup>st</sup> and 2<sup>nd</sup> vaccination. 103 104 Consistent with our previous results, older adults possessed high levels of H5 stalk-105 reactive antibodies before vaccination (Fig. 2a). H5 stalk-reactive antibody levels 106 increased slightly in older individuals and more substantially in children after each 107 vaccination (Fig. 2b-c). We observed the highest fold change in H5 stalk-reactive 108 antibody titers in children, whose antibody levels were lower prior to vaccination (Fig. 109 2d). We obtained similar data when we measured antibodies reactive to the full length 110 A/Vietnam/1203/2004 HA vaccine antigen (Fig. 2e-h). Older individuals possessed 111 higher levels of A/Vietnam/1203/2004 HA-reactive antibodies relative to children before 112 vaccination (Fig. 2e) and these antibodies were boosted in participants in all age groups 113 after vaccination (Fig. 2f-g) with the greatest benefit in children (Fig. 2h). Consistent 114 with a recent report<sup>25</sup>, we found that the clade 1 A/Vietnam/1203/2004 H5N1 vaccine 115 elicited antibodies that bound to the more recent antigenically distinct clade 2.3.4.4b HA 116 (Fig. 2i-I). Antibody levels against the clade 1 and clade 2.3.4.4b HAs were similar after 117 vaccination (compare Fig. 2g and Fig. 2k). 118 While some HA stalk antibodies are broadly neutralizing, many of these 119 antibodies protect through Fc receptor-dependent mechanisms such as antibody dependent cellular cytotoxicity (ADCC)<sup>26</sup>. We therefore determined if antibodies elicited 120 121 by the A/Vietnam1203/2004 vaccine neutralized H5 virus or mediated ADCC with 122 matched and mismatched H5 HAs. The vaccine elicited antibodies that neutralized clade 123 1 virus (Extended Data Fig. 4a-c) with larger fold-change titer increases in children

124 (Extended Data Fig. 4d). The clade 1 vaccine antigen also elicited clade 2.3.4.4b

125 neutralizing antibodies in some participants, but this was more sporadic (Extended Data

Fig. 4e-h). ADCC activity against the clade 1 and clade 2.3.4.4b H5N1 viruses was high
in serum from older individuals prior to vaccination (Extended Data Fig. 4i and 4m) and
increased in younger individuals following vaccination (Extended Data Fig. 4j-k and 4no), with the largest ADCC titer fold change in children following vaccination (Extended
Data Fig. 4I and 4p).

131 Finally, we directly compared antibody titers from our healthy donors (Fig. 1) with 132 pre-vaccination titers from adults from the H5 vaccine trials (Fig. 2). Since these 133 samples were collected 12 years apart (2005 versus 2017), we were able to determine if 134 H5 antibody levels were more closely associated with birth year or age (Fig. 3a-b). 135 Consistent with immune imprinting, antibody levels were similar across these datasets 136 when plotted as a function of birth year (Fig. 3a) but different when plotted as a function 137 of age (Fig. 3b). Using two different statistical approaches, we found that titers to full 138 length H5 proteins from clade 1 and clade 2.3.4.4b (but not to the H5 stalk) had stronger 139 statistical associations with year of birth and group 1 imprinting probability than with age 140 (**Tables S2** and **S3**). Antibody levels were less strongly associated with H1N1 imprinting 141 than with group 1 imprinting, suggesting that initial infections with H1N1 or H2N2 prime 142 antibody responses against clade 1 and clade 2.3.4.4b H5 proteins. Taken together, 143 these analyses corroborate the role of imprinting with group 1 viruses in shaping 144 antibody levels to H5N1 in humans.

Further studies need to be completed to determine if strong immunological imprinting is solely a byproduct of initial influenza virus encounters or if multiple exposures during childhood are required to prime robust memory B cell responses. Our previous studies suggest that heterosubtypic influenza virus infections in ferrets and humans boost HA stalk responses against the originally infecting viral subtype<sup>27</sup>. Longitudinal cohort studies, in which infections and vaccinations are tracked carefully from birth, are required to better understand how childhood exposures impact the

generation of influenza virus antibodies later in life. In our experiments, younger

152

153 individuals possessed lower levels of H5-reactive antibodies prior to vaccination, and it is 154 likely that many of the younger children in our study had not yet been exposed to group 155 1 viruses at the time of sample collection. 156 Our study has limitations. For our vaccination studies, we analyzed serum 157 samples from 3 separate clinical studies to compare antibody responses elicited in 158 individuals with diverse birth years. The same vaccine formulation, dose, and 159 vaccination schedule were used in all 3 clinical studies, so it is unlikely that the observed 160 differences were due to clinical study differences. We only compared antibody 161 responses elicited by unadjuvanted vaccines in our studies. Khurana and colleagues 162 recently reported that adjuvanted clade 1 H5N1 vaccines elicit antibodies with high 163 reactivity to clade 2.3.4.4b H5N1 viruses<sup>25</sup>, and it will be important for future studies to 164 evaluate if there are birth year-related differences in responses to adjuvanted vaccines. 165 We only evaluated antibody responses to HA, and additional studies should be 166 completed to determine if humans possess cross-reactive antibodies against the 167 neuraminidase protein of H5N1. Finally, all our vaccine studies were based on clade 1 168 H5N1 antigens, and future studies should evaluate responses to other vaccine antigens 169 based on more contemporary H5N1 strains. 170 Based on our studies and the observation that H5N1 viruses have typically

170 Based on our studies and the observation that HSNT viruses have typically 171 caused more disease in younger individuals<sup>15,16</sup>, it is possible that older individuals 172 would be partially protected in the event of an H5N1 pandemic. Younger individuals who 173 have fewer group 1 influenza virus exposures would likely benefit more from an H5N1 174 vaccine, even a mismatch stockpiled vaccine<sup>28</sup>. It will be important to continue to test 175 new updated vaccine antigens in individuals with diverse birth years, including children. 176 It will also be important to closely monitor clade 2.3.4.4b H5N1 virus circulating in wild

- and domestic animals, as well as spillover infections of humans, so that we can continueto evaluate the pandemic risk of these viruses.
- 179

### 180 Acknowledgments

- 181 We thank the Penn Medicine BioBank as a resource for obtaining serum from humans
- 182 with different birth years. We thank NIAID and the VTEU clinical study teams from DMID
- 183 04-063, DMID 04-076, and DMID04-0077 for providing sera samples from clinical
- 184 studies. This project was funded in part with Federal funds from the National Institute of
- 185 Allergy and Infectious Diseases, National Institutes of Health, Department of Health and
- 186 Human Services, under Contract Nos. 75N93021C00015 (S.E.H. and S.C.) and grant
- 187 numbers R01Al08686 (S.E.H.). S.E.H. holds an Investigators in the Pathogenesis of
- 188 Infectious Disease Awards from the Burroughs Wellcome Fund.
- 189

## **190** Author Contributions Statement

191 S.E.H., T.A.G., J.L., S.H.L., G.S., C.F., and J.J.S.S. designed the experiments. T.A.G.,

192 J.L., S.H.L., G.S., J.J.S.S., G.H., C.F., R.K.A., N.Y., J.O., K.A.H., and T.E. completed

experiments and analyzed data. K.K., M.C.V., and S.Co. performed modeling studies.

194 S.E.H. wrote the manuscript and all authors contributed to editing the manuscript. D.S.,

195 S.Ch., S.Co., and S.E.H. supervised experiments and data analyses. S.E.H. obtained196 funding for the study.

197

#### **198 Competing Interests Statement**

S.E.H. is a co-inventor on patents that describe the use of nucleoside-modified mRNA as
a vaccine platform. S.E.H reports receiving consulting fees from Sanofi, Pfizer, Lumen,
Novavax, and Merck. T.A.G. was an employee of the University of Pennsylvania when the

- 202 work was completed and is now an employee of GSK. The authors declare no other
- 203 competing interests.

205 206	Figure Legends Fig. 1. Group 1 immune imprinting primes robust H5-reactive antibody responses.
207	(a) Group 1 (blue) and group 2 (red) influenza viruses have circulated at distinct times
208	since 1918. Sera samples were collected from healthy donors (n=121) at the Hospital of
209	the University of Pennsylvania in 2017 and we quantified IgG binding in ELISA to
210	'headless' A/California/4/2009 H1 stalk (b), 'headless' A/Vietnam/1203/2004 H5 stalk (c),
211	'headless' A/Finland/486/2004 H3 stalk ( <b>d</b> ), A/Shanghai/02/2013 H7 stalk ( <b>e</b> ), a clade 1
212	A/Vietnam/1203/2004 full length H5 HA (f) and a clade 2.3.4.4b A/Pheasant/New
213	York/22-009066-011/2022 full length H5 HA (g). (b-g) Vertical dashed lines mark years
214	of the 1957 H2N2 and 1968 H3N2 pandemics and 1977 reemergence of H1N1. Each
215	circle represents a geometric mean antibody titer in serum from a single donor from two
216	independent replicates, and the trend lines are locally estimated scatterplot smoothing
217	(LOESS) curves (smoothing parameter = 0.4, degree = 2) with 95% confidence intervals.
218	
219	Fig. 2. H5N1 vaccination elicits strong H5 stalk-reactive antibodies in children.
220	Sera samples were obtained from participants (n=100) before (day 0) and 28 days after
221	receiving a first and second dose of an unadjuvanted A/Vietnam/1203/2004 H5N1
222	vaccine in 2005-2006. We quantified IgG binding to a 'headless' A/Vietnam/1203/2004
223	H5 stalk ( <b>a-c</b> ), and we calculated titer fold change by dividing day 28 post-boost titers by
224	day 0 titers ( <b>d</b> ). We also measured antibody binding and fold change to clade 1
225	A/Vietnam/1203/2004 full length H5 (e-h) and clade 2.3.4.4b A/Pheasant/New York/22-
226	009066-011/2022 full length H5 (i-I). Vertical dashed lines mark years of the 1957 H2N2

and 1968 H3N2 pandemics and 1977 reemergence of H1N1. Each circle represents a

- 228 geometric mean antibody titer in serum from a single donor from two independent
- replicates. Samples from adults are grey and children are blue. Trend lines are locally

- 230 estimated scatterplot smoothing (LOESS) curves (smoothing parameter = 0.4, degree =
- 231 2) with 95% confidence intervals, fitted to adult samples.
- 232

# Fig. 3. H5-rective antibody levels correlate better with birth year compared to age.

- Antibody titers in samples collected in 2005 (yellow) and 2017 (blue) against H5 stalk,
- clade 1 A/Vietnam/1203/2004 full length H5, and clade 2.3.4.4b A/Pheasant/New
- 236 York/22-009066-011/2022 full length H5 are shown as a function of birth year (a) and
- age (**b**). Vertical dashed lines mark years of the 1957 H2N2 and 1968 H3N2 pandemics
- and 1977 reemergence of H1N1 (a). Each circle represents a geometric mean antibody
- titer in serum from a single donor from two independent replicates. Trend lines are
- locally estimated scatterplot smoothing (LOESS) curves (smoothing parameter = 0.65,
- 241 degree = 2) with 95% confidence intervals, fitted to adult samples.
- 242
- 243
- 244

#### 245 **References**

- Lewis, N.S., *et al.* Emergence and spread of novel H5N8, H5N5 and H5N1 clade
   2.3.4.4 highly pathogenic avian influenza in 2020. *Emerging Microbes & Infections* 10, 148-151 (2021).
- 249
  2. Caliendo, V., *et al.* Transatlantic spread of highly pathogenic avian influenza
  250
  251
  Caliendo, V., *et al.* Transatlantic spread of highly pathogenic avian influenza
  251
  Caliendo, V., *et al.* Transatlantic spread of highly pathogenic avian influenza
  250
  251
  251
  251
- 252 3. King, J., et al. Highly pathogenic avian influenza virus incursions of subtype
  253 H5N8, H5N5, H5N1, H5N4, and H5N3 in Germany during 2020-21. Virus
  254 Evolution 8(2022).
- Adlhoch, C., *et al.* Avian influenza overview December 2022 March 2023. *Efsa j* 256 **21**, e07917 (2023).
- 2575.Rijks, J.M., et al. Highly Pathogenic Avian Influenza A(H5N1) Virus in Wild Red258Foxes, the Netherlands, 2021. Emerg Infect Dis 27, 2960-2962 (2021).
- 259 6. Puryear, W., et al. Outbreak of Highly Pathogenic Avian Influenza H5N1 in New
  260 England Seals. *bioRxiv*, 2022.2007.2029.501155 (2022).
- 7. Pyankova, O.G., *et al.* Isolation of clade 2.3.4.4b A(H5N8), a highly pathogenic
  avian influenza virus, from a worker during an outbreak on a poultry farm,
  Russia, December 2020. *Euro Surveill* **26**(2021).
- Agüero, M., *et al.* Highly pathogenic avian influenza A(H5N1) virus infection in farmed minks, Spain, October 2022. *Euro Surveill* 28(2023).
- Nguyen, T.Q., Hutter, C., Markin, A., Thomas, M., Lantz, K., Killian, M.L., Janzen,
   G.M., Vijendran, S., Wagle, S., Inderski, B., Magstadt, D.R., Li, G., Diel, D.G.,
   Frye, E.A., Dmitrov, K.M., Swinford, A.K., Thompson, A.C., Snevik, K.R., Suarez,
   D.L., Spackman, E., Lakin, S.M., Ahola, S.C., Johnson, K.R., Baker, A.L., Robbe-
- Austerman, S., Torchetti, M.K., Anderson, T.K. Emergence and interstate spread
   of highly pathogenic avian influenza A(H5N1) in dairy cattle. *bioRxiv* <u>https://doi.org/10.1101/2024.05.01.591751(2024</u>).
- Burrough, E.R., *et al.* Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b
  Virus Infection in Domestic Dairy Cattle and Cats, United States, 2024. *Emerg Infect Dis* 30, 1335-1343 (2024).
- 276 11. Santos, J.J.S., *et al.* Bovine H5N1 influenza virus binds poorly to human-type sialic acid receptors. *bioRxiv* (2024).
- 278 12. Chopra, P., *et al.* Receptor Binding Specificity of a Bovine A(H5N1) Influenza
  279 Virus. *bioRxiv* (2024).
- 13. Neumann, G. & Kawaoka, Y. Highly pathogenic H5N1 avian influenza virus outbreak in cattle: the knowns and unknowns. *Nat Rev Microbiol* 22, 525-526 (2024).
- 14. Moratorio, G., *et al.* H5N1 influenza: Urgent questions and directions. *Cell* 187, 4546-4548 (2024).
- 285 15. Qin, Y., *et al.* Differences in the Epidemiology of Human Cases of Avian
  286 Influenza A(H7N9) and A(H5N1) Viruses Infection. *Clinical infectious diseases :*287 *an official publication of the Infectious Diseases Society of America* **61**, 563-571
  288 (2015).
- 289 16. Cowling, B.J., *et al.* Comparative epidemiology of human infections with avian
  290 influenza A H7N9 and H5N1 viruses in China: a population-based study of
  291 laboratory-confirmed cases. *Lancet* **382**, 129-137 (2013).
- 292 17. Krammer, F., et al. Influenza. Nat Rev Dis Primers 4, 3 (2018).

293 294 295	18.	Gostic, K.M., Ambrose, M., Worobey, M. & Lloyd-Smith, J.O. Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. <i>Science</i> <b>354</b> , 722-726 (2016)
296 297	19.	Nachbagauer, R., et al. Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans mBio 7, e01996-
298		01915 (2016).
299	20.	Yassine, H.M., et al. Use of Hemagglutinin Stem Probes Demonstrate
300		Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera.
301		Scientific reports <b>8</b> , 8628 (2018).
302	21.	Sanchez-de Prada, L., et al. Group 1 and group 2 hemagglutinin stalk antibody
303		response according to age. Frontiers in immunology 14, 1194073 (2023).
304	22.	Ledgerwood, J.E., et al. DNA priming and influenza vaccine immunogenicity: two
305		phase 1 open label randomised clinical trials. <i>Lancet Infect Dis</i> <b>11</b> , 916-924
306	00	(2011).
307	23.	Ellebedy, A.H., et al. Induction of broadly cross-reactive antibody responses to
200		Dressondings of the National Academy of Sciences of the United States of
309		America <b>111</b> 13133-13138 (2014)
311	24	Treanor J.J. Campbell J.D. Zangwill K.M. Rowe T & Wolff M Safety and
312	2	immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. The New
313		England journal of medicine <b>354</b> , 1343-1351 (2006).
314	25.	Khurana, S., et al. Licensed H5N1 vaccines generate cross-neutralizing
315		antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus. Nature
316		medicine (2024).
317	26.	DiLillo, D.J., Palese, P., Wilson, P.C. & Ravetch, J.V. Broadly neutralizing anti-
318		influenza antibodies require Fc receptor engagement for in vivo protection. The
319		Journal of clinical investigation <b>126</b> , 605-610 (2016).
320	27.	Arevalo, C.P., et al. Original antigenic sin priming of influenza virus
321		hemagglutinin stalk antibodies. Proceedings of the National Academy of
322	00	Sciences of the United States of America <b>117</b> , 1/221-1/227 (2020).
323	28.	Webby, R.J. The practical longevity of stockpiled A(H5N1) influenza vaccine.
324		Nature medicine (2024).
325		
326		







Fig. 3





